Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors by Jespers, Willem et al.
molecules
Article
Structure-Based Design of Potent and Selective
Ligands at the Four Adenosine Receptors
Willem Jespers 1, Ana Oliveira 1, Rubén Prieto-Díaz 2, María Majellaro 2, Johan Åqvist 1,
Eddy Sotelo 2 ID and Hugo Gutiérrez-de-Terán 1,* ID
1 Department of Cell and Molecular Biology, Uppsala University, Biomedical Centre (BMC), BOX 596,
SE-751 24 Uppsala, Sweden; willem.jespers@icm.uu.se (W.J.); analuisa.novodeoliveira@icm.uu.se (A.O.);
johan.aqvist@icm.uu.se (J.Å.)
2 Centro Singular Investigación Quimica Biologica e Materiales Moleculares (CIQUS),
Departamento de Quimica Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela,
15782 Santiago de Compostela, Spain; rupridi@gmail.com (R.P.-D.);
maria.majellaro@uniba.it (M.M.); e.sotelo@usc.es (E.S.)
* Correspondence: hugo.gutierrez@icm.uu.se; Tel.: +46(0)18-471-5056
Received: 20 October 2017; Accepted: 8 November 2017; Published: 10 November 2017
Abstract: The four receptors that signal for adenosine, A1, A2A, A2B and A3 ARs, belong to the
superfamily of G protein-coupled receptors (GPCRs). They mediate a number of (patho)physiological
functions and have attracted the interest of the biopharmaceutical sector for decades as potential
drug targets. The many crystal structures of the A2A, and lately the A1 ARs, allow for the use
of advanced computational, structure-based ligand design methodologies. Over the last decade,
we have assessed the efficient synthesis of novel ligands specifically addressed to each of the four
ARs. We herein review and update the results of this program with particular focus on molecular
dynamics (MD) and free energy perturbation (FEP) protocols. The first in silico mutagenesis on the
A1AR here reported allows understanding the specificity and high affinity of the xanthine-antagonist
8-Cyclopentyl-1,3-dipropylxanthine (DPCPX). On the A2AAR, we demonstrate how FEP simulations
can distinguish the conformational selectivity of a recent series of partial agonists. These novel results
are complemented with the revision of the first series of enantiospecific antagonists on the A2BAR,
and the use of FEP as a tool for bioisosteric design on the A3AR.
Keywords: free energy perturbation (FEP); G protein-coupled receptors (GPCRs); molecular
dynamics (MD) simulations; structure-based drug design (SBDD)
1. Introduction
The superfamily of G protein-coupled receptors (GPCRs), which encompasses targets for more
than 30% of marketed drugs [1], was traditionally relegated from the field of structure-based
drug design (SBDD) due to the inherent difficulty of solving the structure of these membrane
receptors. However, recent advancements in membrane crystallography in the past decade have
led to an explosive growth in available crystal structures, currently comprising 196 receptor–ligand
complexes [2]. A particularly privileged family in this sense is the adenosine receptors (ARs), with
several complexes of the A2A and lately for the A1 ARs deposited in the PDB. These structures
can be used to model the remaining A2B and A3 receptor subtypes in the family, thus providing
a full pallet of atomistic models of the AR family. ARs play an essential role in many physiological
processes in the cardiovascular and central nervous systems, and control anti-inflammatory and
immunosuppressive responses. Consequently, this family of receptors is of outstanding interest as
drug targets for cardiovascular, neurodegenerative and autoimmune diseases, as well as cancer [3].
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Over the last decades, a large number of agonists and antagonists have been synthetized and
pharmacologically characterized, accumulating to 25,000 entries in the ChEMBL database, which
have been source of a number of computational screening and SAR analyses [4–7]. The exponential
growth of experimental GPCR structures [8] proved extremely beneficial for the structural biology
and structure-based ligand design of ARs [9,10]. The current repertoire, consisting of several
A2AAR structures in complex with antagonists and agonists, was recently complemented with
fully active conformation of this receptor in ternary complex with a G protein mimic [11], and
two antagonist-bound (inactive) A1AR structures [12,13]. The effects of point mutations on ligand
binding constitute another important information resource for the characterization of receptor–ligand
interactions and receptor activation. Thus, site-directed mutagenesis data further complement the
structural and chemical information, and over 2500 data points are deposited in the GPCRdb [2].
This combination of structural, pharmacological and chemical information allowed the pharmaceutical
SBDD of 1,2,4 triazines as A2AAR antagonists, one of which reached clinical studies for the treatment
of Parkinson’s disease [9].
The family of ARs, and in particular the A2AAR, have become targets for several computational
studies to evaluate methods and protocols proposed in the field of GPCR ligand design [10]. One of
the first topics investigated after the release of the first A2AAR structure was the actual role of water
molecules in ligand binding, studied through molecular dynamics (MD) sampling of the solvent
in the binding cavity [14]. This allowed the identification of water clusters whose displacement
should favor the binding affinity of prospective ligands [15], or of structural waters that should be
considered for antagonist docking and virtual screening (VS) on this receptor [16]. The detailed
structural characterization of the A2AAR also allowed for the estimation of binding free energies,
based on MD sampling. The low affinity of the micromolar antagonist caffeine was rationalized
using the molecular mechanics/Poison-Boltzman surface area (MM/PBSA) method [17], introducing
the idea of a multiple binding mode for this molecule, which was partially supported by recent
crystal structures with xanthine-like antagonists [13,18]. In this area, our group developed a protocol
based on free energy perturbation (FEP) for the estimation of relative binding affinities upon point
mutations [19]. The results of this “in-silico” site directed mutagenesis can be directly compared
to experimentally determined ligand affinity ratios between wild-type (WT) and mutant receptor
variants, coming from the numerous site-directed mutagenesis studies as we will discuss here for the
case of the A2AAR [20,21]. The method, which was initially developed and later applied in other GPCR
systems [19,22], overcomes the convergence problems associated with large perturbations and allows
reproducing the effect of point mutations on ligand binding with high precision and convergence.
During the last years, our labs have combined FEP and other computational methodologies with
high-throughput synthetic methodologies and pharmacological characterization, to develop various
series of structurally simple, novel AR ligands [23]. Our SBDD protocol includes homology modeling,
protein–ligand docking, 3D-QSAR, MD and FEP simulations, and was used to assist the design of
novel ligands as well as to predict or rationalize their pharmacological profile [24–32]. The different
series obtained with this strategy, represented in Figure 1, have been optimized to yield potent and
selective antagonists of the different ARs. The first scaffold reported, a 2,4-diarylpyrimidine, was
recently followed by a bioisosteric series of 2,4-diarylpyridines, both of them revealing high affinity
and selectivity as A3AR antagonists [24,25,30]. For the A2B receptor, we have documented the first
non-planar, enantioselective antagonists, and disclosed the reasons of their enantiospecificity [31,32].
The A2AAR emerges as the most attractive target for SBDD within the AR family, due to the existence
of several crystal structures complemented with broad mutagenesis and SAR data. Consequently,
we used this system to train our protocol for in-silico mutagenesis, based on well-converged FEP
calculations [20,21]. Moreover, we went one step further in the design of new ligands and isolated,
from a series of antagonists, a group of compounds that presented a pharmacological profile of partial
agonists, where we identified a prolinol moiety as a replacement of the ribose group of classical
agonists [28]. Finally, recently published crystal structures of the A1AR allow for the characterization
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of molecular determinants of high affinity, which we here exemplify with the calculation and
interpretation of the effect of point mutations on the binding affinity of the reference xanthine-like
antagonist DPCPX (see Figure 1).
In the following sections, we review our recent results on the design and characterization of
ligand binding for each of the four ARs, and further complement these studies with new analysis
and calculations. We put the results of this project in the broad perspective of ARs ligand design, and
discuss the methodological developments in our SBDD pipeline, with an impact in the design of novel
ligands for this and other families of receptors.
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2. Results
2.1. A2AAR
The A2AAR is one of the best-characterized GPCRs, with various entries in the PDB including
inactive structures, in complex with eight different antagonists, four active-like structures with agonists,
and o e ful y- ctivated A2AAR, i ternary compl x with an agonist and a mimic of the intracellular
G protein [11]. In addition, this receptor accumulates 42% of the mutagenesis data deposited in the
GPCRdb for the ARs, while 31% of the 26.274 entries in ChEMBL [33] (release 23) report affinities
for this receptor subtype. The vast amount of chemical and structural information corresponds to
the biopharmaceutical interest in this receptor, where antagonists have reached clinical trials as a
nondopaminergic therapy for Parkinson’s disease [34], while the agonist Regadenoson has been
approved by the FDA as a coronary vasodilator [35].
Given this unique combination of mutagenesis and structural information, we have used this
system to fur her develop our i silico mutagenesis approach b sed on FEP [20,21]. The thermodynamic
cycle underly ng this approach was originally developed by Kollman and co-workers to c aracterize
the effect of a single mutation on ligand binding free energies (and catalysis) [36], and consists on
the perturbation of the amino acid sidechain from WT to mutant in both the complex and the apo
versions of the receptor (which acts therefore as the reference state). Starting from this concept, we
developed a dedicated FEP protocol to routinely evaluate affinity shifts for a given ligand to mutant
versions of the receptor, as compared to the WT. Although standard FEP implementations might work
well enough for simple cases (e.g., Serine to Alanine), more drastic mutations (e.g., Tryptophan to
Alanine) are subject to convergence and sampling roblems, usually leading to high hysteresis values
(defined as the difference in the forward and backwards pathway of the s dechain transformation).
In our implem ntation, described in detail in the methods section and applied here to the original
characterization of mutagenesis experiments on the A1AR (see below), the sidechain of the residue to
mutate is gradually annihilated to alanine in a stepwise fashion. With this strategy, we examined the
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effect of 18 alanine mutations reported for the A2AAR for agonist and antagonist binding with high
precision (s.e.m. = 0.7 kcal/mol) and convergence values (average hysteresis of 0.2 kcal/mol) [21].
This analysis revealed effects that were not evident by the sole analysis of crystal structures, such as the
disruption of water-mediated interactions causing decreased antagonist binding observed in mutants
V843.32A, L2946.51A or Ile2747.39A (Ballesteros–Weinstein nomenclature for GPCRs is indicated in
superscripts as X.YY, with X indicating the helix and YY the correlative position relative to the most
conserved residue in the helix, when YY = 50 [37]). Another outcome of such analysis was deciphering
the detrimental effect on agonist binding of the M1775.38A mutation due to an increased solvation of
the binding site that perturbed agonist-receptor interactions. The methodology was then extended to
account for non-alanine mutations, by joining two thermodynamic cycles describing the reduction of a
sidechain, i.e., from WT and mutant, respectively, to a common fragment (e.g., Alanine). This allowed
us to further characterize the effect of 17 non-alanine mutations on agonist binding, again in excellent
agreement with the experimental data [20].
The most traditional and extensive use of FEP calculations on ligand design, however, is to
predict the relative binding affinity between pairs of ligands. In this case, the application involves
a thermodynamic cycle where ligand 1 is transformed into ligand 2 in both the bound and the
reference (i.e., water solvated) states. An example of the application of this technique on antagonist
design can be found in the section covering the A3AR (see below). We herein decided to mix the
idea of a ligand-perturbation with a receptor-comparison in a new thermodynamic cycle, which we
apply to identify the preferred receptor conformational state for different pharmacological classes
of ligands. In theory, the capacity of a ligand to activate the receptor (i.e., agonist potency) can be
related to its specific preference for the active conformation. Therefore, the relative affinities between
two ligands for the inactive and active conformations of the receptor can be qualitatively related
to their relative difference in potency. To illustrate this point, we here perform such calculations
on our recently reported series of thiazolo[5,4-d]pirimidines, designed as potential agonists of the
A2AAR as bioisosteres of the purine ring on the basis of molecular docking and superposition with the
classical agonists (e.g., adenosine, NECA) [28]. The molecules in this series that contain a 7-prolinol
substitution were characterized as a new class of non-nucleoside A2AAR partial agonists, confirming
the hypothesis of the design where the 2-hydroxymethylene moiety of the prolinol would mimic
the interactions of the 2′/3′ hydroxyl groups of the ribose of agonists, observed in all agonist bound
A2AAR crystal structures. To understand the molecular determinants of the functional behavior of
these molecules, we designed a thermodynamic cycle where the partial agonist ligand 10n (containing
prolinol, relative efficacy as compared to NECA > 50%) was transformed in its antagonist analog
lacking the 2-hydroxymethylene group (10m, with a relative efficacy value < 10%), both in the
inactive and active-like A2AAR structures as shown in Figure 2. The results indicate that the loss
of the 2-hydroxymethylene “agonist tag” is more unfavorable in the active-like than in the inactive
receptor structure (∆∆G10m→10n = 1.74 ± 0.29 kcal/mol), which is in qualitative agreement with the
observed reduction in potency between this pair of compounds. Interestingly, the main difference
in the simulations between the inactive and active structures are observed in the interactions of
the 2-hydroxymethylene moiety, where the interaction with S2777.42 in the (unfavored) inactive
conformation is replaced by a hydrogen bond to H2787.43 in the simulations of the active-like structure.
This might explain why there are several partial agonists that exert a higher potency on the S277A7.42
mutant receptor [38]. If followed a similar evaluation of a second pair of compounds within this series
with similar results: The partial agonist denoted as 10d (40% efficacy as compared to NECA) contains a
different substitution pattern on the ring exposed to the extracellular loops (i.e., 4-Cl-phenyl instead of
3,4,5-tris-OMe-phenyl in 10m/10n, see Figure 1), and is transformed into the corresponding antagonist
(10c, 10% efficacy) upon removal of the prolinol moiety. The calculated effect in this pair of ligands
also indicates that the affinity of the partial agonist for the active form of the receptor is favored as
compared to the antagonist. Moreover, the reduced energetic barrier as compared to the 10m/10n
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pair (∆∆G10d→10c = 0.65 ± 0.26 kcal/mol) agrees with the lower experimental difference in the efficacy
between the 10d/10c pair of compounds.Molecules 2017, 22, 1945 5 of 17 
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Figure 2. Thermodynamic cycle showing the relationship between the potency of the ligand pair
10m/10n and the relative free energies of perturbing 10n to 10m in the active-like (blue) and inactive
(orange) structures. The grey sticks represent the conformation of the residues in the active-like
structure as compared to the inactive structure, and vice versa. A ligand that activates the receptor
(partial or full agonist) should in theory have a higher affinity for the active state of that receptor. Thus,
perturbing the (partial) agonist (10n) into an antagonist (10m) should result in an unfavorable change
in binding free energies, as shown here for the 10n→10m transformation.
2.2. A1AR
The adenosine A1 receptor, which plays a significant role in the regulation of neural, renal
an cardiac sys ems [3], was the fir t AR to be characterized [39]. A1AR anta onists have been
predominan ly derivatives of the xanthine scaffold, such as the reference a agonist DPCPX ( ee
Figure 1), allowing alkyl substitutions on the 1 and 3 position while more bulky, cyclic substituents
on the 8 positions proved essential for subtype selectivity. Initial mutagenesis studies indicated
an essential role of T2707.35 (Met in A2AAR and A2BAR, Leu i A3AR) in the accommodation of
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substituents at position 8. This was confirmed by two recently solved crystal structures in complex
with selective xanthine derivatives [12,13]. Besides revealing T2707.35 as a selectivity determinant, the
structures showed a slightly widened area as compared to the A2AAR in the bottom of the binding pocket,
selectively accommodating the substituents at position 1. Finally, the binding pocket of the A1AR was
shown to be unexpectedly large. All these differences deserve a detailed exploration on the basis of MD
and free energy calculations, to understand the specific requirements of ligand binding to this receptor.
We here apply our in silico mutagenesis approach, described below for the case of A2AAR
co-crystallized ligands [20,21], to understand the structural requirements of binding of the selective
xanthine DPCPX to the A1AR. The first stage was to manually dock DPCPX onto the A1AR crystal
structure 5N2S, based on the structural similarity of the co-crystalized ligand PSB36 and DPCPX
(see Figure 3 and Methods). A double hydrogen bond with N2546.55 formed the main anchor point
between the core scaffold and the receptor, similar to many other crystal structure complexes of A1
and A2A ARs.
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Figure 3. (A) Average structure from MD simulations of the DPCPX-A1AR complex (blue) superimposed
with the crystal structure of the same receptor in complex with PSB-036 (PDB 5N2S); and (B) close look
in the binding site, highlighting selected residues for in silico mutagenesis studies (see Table 1).
Although no affinity data is available for DPCPX for the N254A6.55 mutant A1AR, the fact that
many other ligands show severely reduced affinities for N6.55 mutant ARs (37 receptor–ligand pairs in
the GPCRdb) indicate that this residue is essential for ligand binding. To investigate this hypothesis, we
mutated this residue to alanine. As shown in Table 1, the mutation led to unfavorable binding affinities
for the mutant receptor. This effect is of similar magnitude as for the F171AEL2 mutation, which was
shown in literature to result in completely abolished binding [40]. Mutational effects of other residues
within the binding site were also correctly reproduced (Table 1). Particularly interesting is T277A7.41,
the only mutation resulting in favorable binding affinities as compared to WT A1AR. This mutation
has been thoroughly studied in ligand binding, and is included as a thermostabilizing mutant in the
crystal structure 5N2S [13]. Although we correctly capture the favorable effect on ligand binding,
there is an overestimation of the effect of about 2 kcal/mol. Therefore, we ran the same mutation on
another crystal structure (5UEN) of the A1AR, which does not include this thermostabilizing mutation.
This time the calculated effect is milder, in agreement with the experimental data (Table 1).
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Table 1. Mutational effects on DPCPX affinity for A1AR. The experimental affinities were retrieved
from the GPCRdb and the reference(s) are given in brackets. The binding affinity (pKD) was converted
to ∆∆G following ∆∆G = RT·ln (KDMutant/KDWT).
Mutation ∆∆G (kcal/mol)
In Vitro In Silico
F171AEL2 [40] 4.32 a 6.15 ± 0.69
I175AEL2 [40] 0.98 0.26 ± 0.39
M177A5.37 [40] 1.06 1.84 ± 0.46
N254A6.55 ND b 4.14 ± 0.67
T270A7.34 [40] 0.46 0.40 ± 0.48
T277A7.41 [41–43] −0.32 ± 0.19 c −2.77 ± 0.55−0.42 ± 0.54 d
a No detectable binding, the value represents the detection threshold of the experiment; b No experimental value
determined in literature; c An average value and associated s.e.m. were calculated based on the reported values
from literature (n = 3); d Calculations performed on the 5UEN crystal structure.
2.3. A2BAR
The A2BAR is a receptor with low affinity for the natural agonist. It remains silent under
physiological conditions to be rapidly activated during chronic highly oxidative stress conditions
(e.g., hyperglycemia or mast cell activation). For these reasons, it is an attractive target for
inflammatory processes like asthma or colitis, as well as for other diseases like diabetic retinopathy
or cancer [1]. However, because of its poor expression levels and low affinity for standard ligands,
the pharmacological characterization of this receptor is scarce as compared with the rest of the
members of the ARs family. We are consequently engaged in the development of potent and selective
antagonists as novel pharmacological tools to aid in this process. The hypothesis underlying this
project was the idea that ligands with non-planar, stereodiverse topologies would provide additional
selective tools, due to more specific stereoselective ligand-target interactions. We initially designed the
3,4-dihydropyrimidin-2(1H)-one scaffold, which is easily assembled via the Biginelli multicomponent
reaction, an advantage when it comes to develop series of compounds and evaluate their SAR [29].
The promising affinity of some compounds in the initial series, measured as a racemic mixture, was
explored by means of molecular docking on our A2BAR homology model. The model revealed an
enantiospecific binding orientation, suggesting the potential stereoselectivity of this scaffold and
identifying the potentially active isomer (Figure 4). These promising results led to a further exploration
of non-planar derived scaffolds, by structural diversification at face 2 of the diazinone scaffold.
Three series of analogues were developed, namely 3-deaza[pyridin-2(1H)-ones] and bicyclic and
tricyclic derivatives fused at positions 2,3 or 5,6 of the heterocyclic framework, identifying selective
and potent A2BAR ligands (Figure 1) where the hypothesis of the stereoselectivity was maintained [32].
In a later modification of the original scaffold, we created a series of 2-cyanoimino-4-substituted-
6-methyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxylates [31]. This time the two enantiomers of the most
attractive ligand (16b) were separated by chiral HPLC and their absolute configurations established
by circular dichroism (Figure 4). The biological evaluation of the two enantiomers demonstrated that
the affinity is exclusively due to the (S)-16b enantiomer, validating the prediction from our molecular
modeling studies.
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Figure 4. Synthesis and enantiospecific binding characterization of compound 16b as antagonist of the
A2BAR: (A) the Biginelli multicomponent reaction allows the assembly of the 3,4-dihydropyrimidine
scaffold bearing different diversity points; (B) the chiral resolution identified the S isomer as the
one responsible of the biological affinity of the racemic mixture; and (C) the molecular modeling
confirmed the binding mode previously hypothesized for isomer (S)-16b. The water-density maps
(black mesh) are calculated here by means of MD exploration (grid spacing 1 Å, occupancy > 80%), and
are overlaid with the position of structural waters previously considered during the docking of this
series (red spheres).
The docking studies of these series of non-planar scaffolds were complemented by MD imulations,
which allowed characterizing the role of water molecules in ligand binding. In a first stage, the selected
complex of A2BAR as equilibrated with our PyMemDyn protocol, as implemented in the GPCR-ModSim
web server [44,45] (see Methods). From this analysis, we identified a water molecule that mediated the
interaction between the NH in position 1 of the parent 3,4-dihydropyrimidin-2(1H)-ones and Glu169EL2,
and a second water molecule in the region between the alkoxy substituent and the furan/thienyl
ring, which is actually equivalent to a conserved water molecule observed in the crystal structures of
A2AAR with antagonist ZM241385 [23]. These pair of water molecules were maintained in successive
docking runs for the expanded series of compounds, verifying their potential role in mediating this
inter and intra molecular interactions [29,31,32]. We here provide further support for the existence
of these structural water molecules, by means of an MD exploration of the solvent in the binding
site (see methods). The idea is that the structural water molecules, which might favor the binding
of ligands, is reflected in a higher occupancy during the MD trajectories, as we recently showed for
the A3AR (see below and reference [30]). Figure 4 shows the calculated water density maps at 80%
occupancy, supporting the position of the two water molecules discussed above, mediating interactions
between the ligand and E170EL2 as well as the intramolecular interaction between the 2-furan and
esther groups of the ligand.
2.4. A3AR
The identific tion of A3AR chemical modulators would help in the development of novel drugs
for the pathologies in hich this receptor is involved, such a glaucoma, infl mmation, asthma and
COPD, as well as s veral types of cancer. The medicinal chemistry d veloped aroun thi receptor
also responds to growing demand for pharmacological tools to study the (pato)physiology of the
A3AR, and i clud s the development of agonists and antagonists, as well s radiolabeled versions of
these [46,47].
Our initial efforts in this area resulted in the report of several potent and selective antagonists
with a monocyclic pyrimidine scaffold (compound ISVY130, Figure 1) [24]. The pyrimidine core,
being part of the heterocyclic moiety of the endogenous adenosine, is a recurrent substructural motif
within bi- and tricyclic AR antagonists. The functionalized pyrimidine template could be decorated in
a divergent and parallel fashion with one alkilamino substituent (L1) and two symmetric aromatic
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substitution points (L2 and L3, see Figure 5), by means of the well-established Suzuki–Miyaura
cross-coupling reaction to a collection of commercially available boronic acids. The initial series of
structures combined structural simplicity with a low molecular weight (MW < 350), allowing for
optimization during the subsequent hit-to-lead process [24]. This process was assessed by systematic
docking on our A3AR homology model and the consensus binding mode obtained featured interactions
with well-conserved residues in the ARs: the double hydrogen bond of the key residue Asn2506.55 with
both the exocyclic amido group and the closest nitrogen in the pyrimidine scaffold, and a π-stacking
interaction with Phe168EL2 complemented by hydrophobic interactions with Leu2466.51 (Figure 5).
In addition, this binding pose identified selectivity hotspots on the extracellular area around the L1
region: Leu7.35 in TM7 (Thr/Met/Met on A1/A2A/A2B, respectively) Ile6.58 (Val on the remaining
ARs) and Val5.30 in EL2 (otherwise Glu in the family). The binding mode and interactions identified
were later supported by a crystal structure of the A2AAR in complex with another monocyclic scaffold,
i.e., 1,2,4-triazine, also bearing aryl substitutions [34]. The biological superposition obtained from
the consensus docking was the starting point for a 3D-QSAR model with the second generation of
GRid INdependent Descriptors (GRIND-2), used to rationalize and further optimize the three points of
diversity of this scaffold. The first model was built on the initial series of 62 compounds, and showed
excellent correlation with the experimental data (r2 = 0.86) and good predictive power (q2 = 0.62).
Based on this model, we investigated the role on ligand binding of different methoxyphenyl fragments
of the L2/L3 diaryl substituents of the 4-amidopyrimidine scaffold. The increased selectivity of these
series confirmed a second A3AR selective hotspot created by serines at positions 6.52 (His in the
other ARs) and 5.42 (Asn in the other ARs), located deeper at the TM5-TM6 interface, which create
a cavity that accommodates the meta- and/or para-methoxy groups of the most potent and selective
compounds [25].
The exploration of the pyrimidine scaffold included the characterization of the two isomeric series,
i.e., 2-amidopyrimidines and 4-amidopyrimidines, differing in the position of the second nitrogen (N1)
in the pyrimidine ring. The 3D-QSAR model suggested a role of this nitrogen in the affinity of these
compounds, presumably by interaction with a potentially conserved structural water molecule within
ARs linked to Ser2717.42, for which evidence in the hA3AR homology model was suggested by a GRID
analysis with a water probe [24]. To further explore the complex effect of a “necessary nitrogen” [48]
in the structure–activity (SAR) of these heterocycles, we designed a new series of bioisosteres derived
from the 4-acetamidopyrimidine scaffold, i.e., lacking this nitrogen atom [30] (Figure 5). The most
potent pyridines obtained displayed affinity values in the low nanomolar range, comparable to the best
pyrimidines of the former series, maintaining the excellent selectivity profile toward the remaining ARs.
The affinity data of the two series remained within the same nanomolar range, which confirmed our
design of the bioisosteric replacement. However, a closer look into the data revealed that the nitrogen
replacement by CH led to a small to moderate decrease in binding affinity in most compounds within
the pyridine series. This would be indeed in line with our previous hypothesis that the second nitrogen
would stabilize a water molecule (Figure 5) [24], which in analogy with the latest high resolution
crystal structures of the A2AAR, could be part of a water network in the deep cavity of the binding site.
A comparative MD sampling of the solvent in the two situations (i.e., pyridine and pyrimidine bound
states), revealed a specific increase in water densities around the second nitrogen of the pyrimidine,
as compared to the A3AR-pyridine complex, thus supporting the idea of a water network stabilized
by the binding of a molecule bearing the pyrimidine scaffold [30]. We therefore performed FEP
simulations, which allowed to quantitatively estimating an understanding the origin of the relative
binding affinities between analogous pairs of pyridine/pyrimidine compounds. The calculations,
which essentially consisted of the N→CH perturbation in the ring, were in remarkable agreement with
the experimental data, reproducing the small effect (8 fold loss in binding affinity) in the non-selective
diphenyl substituted pair of compounds, as well as the moderate (30 fold) loss of affinity observed
for the most potent compound in the parent pyrimidine series (4-metoxyphenyl derivative, ISVY130,
and the corresponding pyridine ISVY177, see Figure 5) [30]. An extreme case was the complete
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loss in affinity observed for the 2,4-dimethoxyphenyl derivative, which in our models allowed us
to determine the most probable binding orientation based on FEP calculations. The 2,4-dimethoxy
substituted series could theoretically be accommodated in the binding pocket in four different ways, i.e.,
depending on the “upwards” or “downwards” orientation of each of the two 2-methoxy substituents,
and we ranked each possibility by running parallel FEP calculations on each of them. The results
(Figure 5) showed that only the two poses that accommodate the 2-methoxy on L2 looking upwards,
i.e., making an additional interaction with Asn2506.55, could reproduce the loss in affinity due to
the pyrimidine-pyridine perturbation, illustrating the utility of FEP protocols to identify the correct
binding mode.
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Figure 5. (A) Effect of the bioisosteric replacement of pyrimidine (left) by pyridine (right), showing
the transformation of N into CH simulated by FEP. The increased affinity in the pyrimidine could
be explained by the stabilization of a hydration site as part of a water-network in the binding cavity;
(B) Binding orientation, common to the two series, is shown for pyridine ISVY177; (C) Experimental
change in binding affinities for each pair of compounds between the two series, with correlation
between the corresponding experimental and calculated free energy differences indicated for three
selected pairs of compounds (red boxes).
3. Discussion
Adenosine receptors have emerged as one of the most extensively characterized families of
GPCRs. Eff rts of the academia and the pharmaceutical industry led to a vast amo t of accumulated
pharmacological, biochemical and structural data, providing a highly detailed understanding of lig nd
binding and recept r function. Together with the tremendou increase of available crysta struc ures,
SBDD on ARs has particularly atured over the past decade. While this is nicely illustrated by
the pharmaceutical development of triazine scaffolds as A2AAR ntagonists [9], we focus here on
the understanding of ligand binding and evelopment of novel scaffolds for each of the four ARs,
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reviewing and updating the results of a decade of collaborative work between our chemical and
computational academic labs.
Our integrative approach of efficient synthesis, computational modeling and biological
characterization allowed obtaining substantial amounts of novel, chemically simple and selective AR
ligands, susceptible of further optimization. In addition, the biological data generated from our new
molecules provide the necessary starting point to test our modeling hypotheses, leading to a more
complete understanding of ligand binding and receptor activation processes. The antagonists and
partial agonists of the A2AAR here discussed provide a unique example of understanding ligand
functionality on the basis of structural and computational analysis. Our calculations comparing the
binding of each molecule type to the active and inactive conformations of the receptor are the first
example of a thermodynamic cycle that maps the FEP results to the distinction of pharmacological
classes of ligands, going one step further on the recent use of this technology on GPCRs. Future
studies will be aimed at the applicability of that approach in the design of novel, non-ribose agonists
for ARs. The FEP calculations here reported were set up based on our previously published A2AAR
antagonist and agonist binding models, and it demonstrates that FEP calculations can be routinely
used in drug design once the system is setup and validated, which is the most time-consuming and
human-demanding stage.
The recently crystallized A1AR inactive structure, combined with the amount of mutagenesis
data about antagonist binding to the reference xantine DPCPX, motivated the exploration of the
energetic and atomic details of antagonist binding to this receptor here reported, using our “in silico”
mutagenesis approach. Our results show excellent agreement with experimental data, giving insights
in the determinants of high affinity ligand binding to this receptor and providing us with a new
model for future ligand design for this receptor. This approach allows the prediction of the effects of
mutations on ligand binding in a systematic and routinely applicable fashion, which is very attractive
for the molecular characterization of ligand selectivity between closely related receptors. As we show
here with the recent case of the A1AR, and previously with the A2AAR [20,21], the highest potential of
this technique is in combination with experimental mutagenesis and crystal structures, but that can
easily be extended to other GPCR systems.
For the remaining ARs (A2B and A3 ARs), there is yet no crystal structure available. However,
even in these cases we show how homology models with enough quality can be generated to
characterize, via molecular simulations, the molecular interactions responsible of changes in ligand
binding affinities. This way we could optimize and understand the enantiospecific binding of
a novel series of A2BAR chiral antagonists, including spurious effects as delicate as water mediated
interactions. Water-mediated interactions were also found to be the key element to design and further
test the bioisosteric replacement of pyrimidines by pyridines in the A3AR, via FEP simulations on our
homology-model of this receptor.
In conclusion, we provide here an overview of our systematic design of new AR ligands,
showcasing the applicability of our integrative approach to answer key questions in SBDD on ARs.
4. Materials and Methods
4.1. Preparation of Starting Receptor Structures
The crystal structures of the human A1 (PDB codes 5n2s, with antagonist PBS36 [13], and 5uen,
with covalent antagonist DU172 [12]) and A2A ARs (PDB code 4eiy in complex with antagonist
ZM241385 [49] and PDB ID 2ydo in complex with the agonist adenosine [50]) were retrieved from
the Protein Data Bank, while the corresponding inactive conformations of A2B and A3 ARs were
generated by homology modeling, using the first crystal structure of A2AAR [51] as a template, as
described in references [24,29] (sequence ID with the template is 50% for A2BAR and 41% for A3AR).
The initial receptor structures were subject to some refinement as follows before docking and MD
simulations: (i) Deletion of the engineered fusion proteins in the crystal structures, reverting the
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thermostabilyzing mutations (i.e., A1AR crystal structure) and building the missing loop segments
with Modeller [52]; additional refinement of modeled loops in homology-modeling structures was
done using the LoopModeler routine [53]. (ii) Addition of protons and assessment of Asn/Gln/His
rotamers and protonation states was performed using Molprobity Web server (http://molprobity.
biochem.duke.edu/). In all cases, Asp, Glu, Lys and Arg residues were assigned in their default
charged state, and the His residues were modeled as neutral with the proton on Nδ in all cases
except for His155ECL2 and His2506.52 (protonated on Nε), His264ECL3 (A2A, considered in its positively
charged state), and His278 (A1, considered in its protonated state as determined for inactive ARs
in [44]); (iii) Energy minimization was performed using Schrödinger suite, in the case of homology
models [54].
4.2. Ligand Docking
The different docking explorations on each AR here reported followed the same scheme: Ligands
were build and optimized in the 3D using the Maestro graphical interface and the LigPrep utility from
the Schrödinger suite [55]. For the series of enantiospecific ligands, this included considering R and
the S stereoisomer and possible tautomers in parallel dockings. Each ligand was docked 20 times
with default (high accuracy) genetic algorithm (GA) search parameters, using the scoring function
Chemscore as implemented in GOLD [56] and allowing full flexibility for the ligand, including flipping
of amide bonds. The search sphere was centered on the side chain (CD1) of Ile7.39 and expanded with
a radius of 15 Å, thus ensuring a generous enough search space comprising the orthosteric binding
site experimentally determined for adenosine receptors. In the A2BAR, two water molecules were
considered in the binding cavity, as explored here by MD simulations (see below). In this case, we
used the option toggle trans_spin 2 in GOLD, meaning that the water contribution is only included if it
produces an increase in the predicted scoring and hydrogen bond network is optimized, combined
with the assemble structure option in GOLD to account for the two rotamers of Asn6.55. The criterion
for the selection of docking poses was based on a combination of the Chemscore ranking and the
population (convergence) of the solutions according to a clustering criterion of 1 Å.
4.3. Membrane Insertion, Molecular Dynamics Equilibration and Water Sampling
The receptor structure was inserted into the membrane, solvated and submitted to the MD
equilibration protocol PyMemDyn, as implemented in GPCR-ModSim web server [44,45]. Briefly,
the protein–ligand complex was inserted in an appropriate orientation in a POPC lipid bilayer soaked
with bulk water. The simulation box was created with a hexagonal-prism geometry, which was
energy-minimized and carefully equilibrated using periodic boundary conditions (PBC) and the NPT
ensemble with the GROMACS simulation package [57]. The MD equilibration scheme included
a gradual release of harmonic restraints on protein heavy atoms for 2.5 ns, until only weak backbone
restraints were retained on the protein for an additional 2.5 ns. In the case when this equilibration was
performed in receptor–ligand complexes, the ligand heavy atoms were also restrained during the first
2.5 ns, with similar progressive decrease in force constants as protein heavy atoms.
For the determination of putative water molecules in the binding site, the final snapshot of the
membrane–receptor equilibration of the A2BAR was transferred into the MD package Q [58] for MD
simulations under spherical boundary conditions (SBC). The MD sampling of the solvent consisted
on 10 replicates of 5 ns each, within a sphere of 15 Å around Asn2506.55, where all protein atoms
were restrained with a 5 kcal/mol/Å2 (see next section for detailed parameters of SBC simulations).
The occupancy of the solvent in points of a grid of 1 Å mesh was analyzed with the Volmap tool
implemented in the VMD software package [59].
4.4. Free Energy Perturbation Simulations
The equilibrated binding site of the A1 and A2A AR complexes obtained in stage 4.3 were
transferred to Q to perform FEP calculations under SBC [58]. In this cases, the SBC was setup with a
Molecules 2017, 22, 1945 13 of 17
sphere of 25 Å radius centered on the center of geometry of the ligand, with the following parameters
for the MD simulations: protein atoms in the boundary of the sphere (22–25 Å outer shell) are under
positional restraints of 20 kcal/mol/Å2, while solvent atoms are subject to polarization and radial
restrains using the surface constrained all-atom solvent (SCAAS) model to mimic the properties of bulk
water at the sphere surface [58,60]. Atoms lying outside the simulation sphere are tightly constrained
(200 kcal/mol/Å2 force constant) and excluded from the calculation of non-bonded interactions.
Long range electrostatics interactions beyond a 10 Å cut off were treated with the local reaction field
method [61], except for the atoms undergoing the FEP transformation where no cutoff was applied.
Solvent bond and angles were constrained using the SHAKE algorithm [62]. All titratable residues
outside the sphere were neutralized and the residues within the sphere manually checked for their
most probable state (as detailed in Section 4.1). Residue parameters were translated from the latest
version of the OPLSAA/M force field [63], whereas the rest of the parameters for the ligand and lipids
were inherited from stage 4.3. The simulation sphere was warmed up during a first equilibration
period of 0.61 nanoseconds from 0.1 to 298 K, where an initial restraint of 25 kcal/mol/Å2 imposed
on all heavy atoms was slowly released. Thereafter, the system was subject to unrestrained MD
simulations, starting with a 0.25 nanosecond unbiased equilibration period which is followed by the
FEP sampling, where atom transformations occur along a linear lambda (λ) parameter between initial
and ending states, equally divided into λ-windows. The sampling consists of 10 replica MD simulations
with different initial velocities, each of them with 1 fs time step and a number of 10.000 steps per
λ-window. The FEP protocol is divided into separate stages, each of them consisting of the same
number λ-windows (for details see [20,21]): initially, the partial charges are removed, a stage that is
followed by transformation of the regular van der Waals potentials into smoother soft-core potentials,
before the annihilation of the corresponding group of atoms, and finally restoring the partial charges
of the final species. For the aminoacid sidechain mutation, these stages (consisting in the current
simulations of 21 λ-windows each) are consequently applied to groups of atoms (charge groups),
starting from the one with a higher topological distance from the Cα. To fulfill a thermodynamic
cycle in these cases, the same sidechain annihilation is simulated in the apo structure of the protein.
For the ligand perturbations, the four stages are applied to the group of atoms undergoing change
(i.e., CH2OH to H), each stage sampled along 51 λ-windows, and parallel transformations of the
ligand are done in an equivalent sphere of water (reference state for the thermodynamic cycle). In all
reference simulations, the same parameters apply (i.e., sphere size, simulation time, etc.), and the
relative binding free energy difference was estimated by solving the thermodynamic cycle utilizing the
standard Zwanzig exponential formula [64].
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